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The National Lung Screening Trial demonstrated a significant mortality benefit for patients at high risk for lung
cancer undergoing serial low-doseCT.Currently, theNational ComprehensiveCancerNetwork and several United
States–based professional associations recommend CT Lung screening for high-risk patients. In the absence of
established reimbursement, the authors modeled and implemented a free low-dose CT lung cancer screening
program to provide equitable access to all eligible patients. Elements of the program reported in this article include a
decentralized referral network, centralized program coordination, structured reporting, and a patient data manage-
ment system.The experience and initial results observed in this clinical setting closelymatch the performancemetrics
of the National Lung Screening Trial with regard to cancer detection and incidental findings rates. To eliminate
health care disparities a vigorous lobbying effort will be needed to expedite reimbursement and make CT lung
screening equally available to all patients at high-risk.
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t
cBACKGROUND
Lung cancer causes more deaths among men and
women in the United States than breast, colorectal,
and prostate cancers combined, with approximately
450 people dying from lung cancer every day [1].
espite continuing advancements in surgery, radia-
ion, and chemotherapy, lung cancer remains a highly
ethal disease, with 16% overall 5-year survival only
arginally improved from 12% in the 1970s [2]. Al-
hough primary prevention (smoking cessation) has
aved countless lives by decreasing the rate of smoking
rom40% in 1965 to20% today [3], many former
eavy smokers remain at high risk and now represent
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586he largest group of patients diagnosed with lung can-
er [4]. In fact, given the large number of former heavy
smokers in the aging baby boom population, lung
cancer mortality seems poised to rise in the absence of
effective secondary prevention (screening) [5].
In 2011, the National Lung Screening Trial
(NLST) reported a 20% lung cancer–specific mortal-
ity benefit in high-risk current and former heavy
smokers who underwent 3 rounds of annual low-dose
CT (LDCT) lung screening compared with annual
chest radiography [6]. Shortly after publication of the
results of this large, National Cancer Institute–spon-
sored, randomized controlled trial, the National
Comprehensive Cancer Network (NCCN) released
guidelines recommending annual LDCT lung screen-
ing for two specific groups of high-risk individuals
meeting stringent criteria [7].
Group 1 (NLST population, NCCN category 1 rec-
ommendation—uniform consensus based on high-level
evidence):
● 55-74 years old
● At least 30 pack-year smoking history
● Current or former smokers (quit within past 15 years)
Group 2 (NCCN category 2B recommendation—
consensus based on lower level evidence):● 50 years old
© 2013 American College of Radiology
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McKee et al/Free CT Lung Cancer Screening 587● 20 pack year smoking history
● Current or former smokers (quit for any length of
time)
● One additional lung cancer risk factor
Lahey Hospital & Medical Center subsequently
tasked a multidisciplinary steering committee to design
and implement an NCCN Guidelines®-based CT lung
ancer screening program to commence January 9, 2012.
he committee included representatives from radiology,
ulmonology, radiation oncology, medical oncology, in-
ernal medicine, administration, finance, philanthropy,
usiness development, and marketing. In this article, we
eport the critical elements of our lung cancer screening
rogram and our initial results, and we conclude by high-
ighting points of discussion about lung screening in
eneral.
PATIENT ACCESS
The most important and vexing decision we made
during the conception of our screening program was
whether to charge for the screening examinations.
Most public and private payers, including CMS, cur-
rently do not reimburse for CT lung screening, with a
few notable exceptions [8-11].
Self-pay rates for CT lung screening (ranging from
99 to $1,000) create access disparities among high-risk
ndividuals of varying financial means [12]. Out-of-
ocket costs also discourage asymptomatic high-risk
atients from undergoing recommended screening ex-
minations. These potent economic and psychological
arriers may in large part explain the commonly reported
ow rates of enrollment in existing self-pay LDCT pro-
rams. Low-volume screening is potentially ineffective,
s 320 individuals need to be screened to save 1 life
ccording to the NLST [6].
To fulfill what we felt was an ethical responsibility
o provide equal screening access to all persons at high
isk regardless of socioeconomic status and to encour-
ge persons at high risk to present for screening, we
ecided to offer CT lung screening at no cost to pa-
ients until CMS and commercial insurers establish
eimbursement on a broad scale. We feel this approach
s consistent with the philosophy of the Patient Pro-
ection and Affordable Care Act, which seeks to
liminate health care disparities and barriers to pre-
entative services [13]. These considerations are at the
ore of our Rescue Lung, Rescue Life movement [14].
ur institutional compliance department required
hat the program fulfill several conditions to be per-
itted to offer free CT lung screening. Objective pa-
ient qualification criteria needed to be established
hat would be followed without exception. No partic-
pant could be billed, not even those with insurance
roviding coverage for CT lung screening. Finally, at
ermination of the free offering, it must be stopped for
ll participants indiscriminately.BUSINESS CONSIDERATIONS
Detailed business modeling of the program was per-
formed before its inception and presented to senior man-
agement for ultimate program approval. The business
model requires the availability of downtime on installed
base CT scanners. Our PET/CT scanner typically is idle
early in themorning, between the injection of radiotracer
and scanning of our first patient. During this downtime,
the PET/CT scanner can accommodate 5 CT lung
screening examinations (25 appointments/week). An
additional 10 appointments/week are available late in the
day, when outpatient activity at the institution decreases
and both technologist staff members and CT scanner
capacity become available. To fully serve our patient
population, we predicted that we would eventually need
approximately 100 to 120 lung screening appoint-
ments/week and therefore estimated the cost of adding
1 dedicated 40-hour overnight and weekend shift (1
technologist and 2 technologist aides), which could ac-
commodate as many as 200 additional screening slots per
week. We assumed that overnight and weekend scan
times would be acceptable to patients, considering the
potential benefit of this examination performed at no
cost.
Although we do not charge for the initial or annual
follow-up screening examinations, workup of any pos-
itive findings requiring downstream diagnostic CT
examinations, clinical assessment, or intervention is
Table 1. CT lung screening program elements
Item Purpose
Toll-free number
(855-CT-CHEST)
Central acceptance and routing of
program-directed patient inquiries
Intake forms Used by general radiology schedulers
to qualify patients and stratify them
into one of the two NCCN high-risk
groups
Call center script Explains to callers the importance of
being asymptomatic at the time
of screening and directs inquiries of
those not meeting criteria for
screening
FAQ document Explains what to expect before, during,
and after screening; gives the
benefits and risks of screening; and
provides information on smoking
cessation at patients’ levels of
understanding
Custom database
application
Pulls patient-specific data from the RIS
to facilitate and manage patient
intake, scheduling, and follow-up
Patient letter
library
Results-specific, standardized patient
notification letters
Program literature Physician-directed program information
literature
Scanning
protocols
Low-dose lung cancer screening
scanning protocols
Note: FAQ  frequently asked questions; NCCN  National Compre-
hensive Cancer Network; RIS  radiology information system.
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588 Journal of the American College of Radiology/Vol. 10 No. 8 August 2013billed to the patient’s insurance in the customary fash-
ion and provides the revenue stream that supports the
program. It should be noted that a universal health
insurance mandate is in effect in the state of Massa-
chusetts [15].
We used inputs from both theNLST data andNCCN
Guidelines® to assess the potential financial impact of
ffering free lung screening. The resulting interactive,
preadsheet-based tool set created for this purpose allows
he operator to perform a sensitivity analysis on the fi-
ancial impact of multiple variables, including the per-
entage of examinations with positive results, the
ercentage of examinations with nodules 4 to 8 mm, the
xpected rate of uninsured individuals, radiologist and
echnologist cost, patient retention rate, annual pa-
ient enrollment, and cancer treatment revenue. Of
ote, at very high scanning volumes (6,000 screen-
ngs/year) 1 full-time equivalent radiologist may be
required to interpret the resulting examinations. By
modeling our own situation, we estimated that in the
first 2 years of our screening program, 60% to 80% of
the revenue available to offset the cost of free screening
would be derived from treating lung cancer. In years 3
to 10, the revenue derived from interval diagnostic
LDCT follow-up of small pulmonary nodules and
lung cancer treatment become equally important rev-
enue sources. These financial models are included with
many other documents on our lung screening program
information CD-ROM, which is available at no cost
to interested centers upon request.
LungRADS 1: Negative - next LDCT in 12 months  
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Solid nodules < 4 mm  
Ground glass nodules < 5 mm  
Characteristically benign findings: atelectasis, scarring, c
LungRADS 2: Benign - next LDCT in 12 months  
Solid nodules > 4 mm but stable for > 2 years
Biopsy proven benign histology (eg, necrotizing granulom
LungRADS 3: Positive, likely benign (< 4% chance of malignan
Solid nodules 4-8  mm or ground glass nodules > 5 mm 
Stable nodules without documented 2 years of stability  
Probable infection/inflammation → next LDCT in 1·2 mo
LungRADS 4: Positive, suspicious for malignancy (> 4% chanc
Growing solid or ground glass nodule 
Solid nodule greater than 8 mm 
Other findings suspicious for malignancy (adenopathy/ef
Pulmonary consultation advised  
LungRADS 5: Known cancer  
Significant incidental findings "Category S":  
Positive(P) or Negative(N) 
Indeterminate breast, liver, kidney, adrenal lesions, aneu
•
•
•
•
•
•10 final assessments (1P, 1N, 2P, 2N, 3P, 3N, 4P, 4N, 5P, 5N) •CT LUNG SCREENING PROGRAM
INFRASTRUCTURE
Lahey Hospital & Medical Center did not participate in
NLST, the International Early Lung Cancer Action Pro-
gram, or any other CT lung screening trial [16]. Therefore,
we needed to build the comprehensive lung cancer screen-
ing program infrastructure from the ground up. Accord-
ingly, a lung cancer screening program coordinator and a
patient navigator position were established. A radiology de-
partment working group consisting of a radiologist, an ad-
ministrative director, CT, PET, and scheduling team
leaders, and a PACS software engineer created the program
elements listed in Table 1.
STANDARDIZED CT LUNG SCREENING
REPORTING SYSTEM
We created a standardized CT lung screening reporting
system (LungRADS) modeled on BI-RADS® [17]. In
ddition to diagnostic categories for lung nodules, the
ystem includes a binary modifier (category S) to address
he occurrence of clinically significant incidental findings
bserved on LDCT lung screening examinations (Fig. 1).
ungRADS also incorporates an NCCN guidelines–
ased nodule lexicon, a structured reporting format, and
nodule size range methodology that reports mean size
n 1-mm ranges (ie, 4-5 mm, 7-8 mm) rather than a
iscrete number (ie, 4, 4.3, or 5.6 mm). This approach
espects the spatial resolution limitation of LDCT, de-
reases interobserver and intraobserver variability, and
voids guideline “trigger” points (4, 6, and 8 mm for
ified granuloma, etc
 
  
next LDCT in 3-6 months
ext LDCT in 6-12 months
s, consider antibiotics  
f malignancy) 
on) 
ms, etc
Fig 1. LungRADS overview.
LDCT  low-dose CT.alc
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NMcKee et al/Free CT Lung Cancer Screening 589solid nodules), which could result in confusion with re-
gard to the appropriate follow-up interval (should a
6-mm nodule undergo 3-month or 6-month follow-
up?). We also anticipate that reporting size ranges will
reduce the need to explain to understandably concerned
patients and physicians why a hypothetical 4.7-mm nod-
ule which previously measured 4.3 mm has not defini-
tively grown.
LungRADS addresses multiple needs that should be
common to all LDCT lung screening programs:
● Facilitate adherence of radiologist recommendations
to screening guidelines (in our specific case, NCCN
Guidelines).
● Facilitate structured, focused training of interpreting
radiologists before credentialing.
● Facilitate the communication of examination results
among the various involved health care providers.
● Allow periodic quality review to assess guideline adher-
ence and ongoing evaluation of performance metrics
such as positive screening rates.
● Facilitate structured database storage and tracking of
findings.
● Automatically generate results-specific patient notifi-
cation letters.
● Facilitate appropriate follow-up examination coding.
Fig 2. CT lung screening patient flow. FAQ  frequently
CCN  National Comprehensive Cancer Network; PCP  p● Triage risk categories within the screened population
and mechanize referral of the small number of patients
(3%-4%) with suspicious findings (LungRADS cate-
gory 4) to multidisciplinary team management.
On the basis of our initial experience, we suggest that
there is a significant opportunity for the ACR to convene
experts in the field to develop a practice guideline for
LDCT lung screening. In that context, we suggest that
LungRADS or a similar structure reporting system
would be a key component of such a guideline, providing
common language to communicate lung screening ex-
amination results across providers and institutions.
PHYSICIAN AND PATIENT EDUCATION
AND OUTREACH
Primary care physicians (PCPs) are best positioned to
help patients decide on the appropriateness of preventa-
tive care interventions such as lung cancer screening.
They have knowledge of their patients’ overall health and
share the downstream responsibility of managing exam-
ination findings. For these reasons, we require PCP or-
ders on all patients before screening.
The PCP provider base represents an established and
experienced decentralized preventive care network essen-
tial to operating a low-cost, high-volume screening pro-
ked questions; IV  intravenous; LDCT  low-dose CT;as
rimary care physician.
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is best leveraged by organizing community information
seminars and advising individual patients and physicians
on an ad hoc basis throughout the screening process.
We mounted an extensive local continuing medical
education campaign with the following main elements
and messages:
● Enable local PCPs to conduct effective informed con-
sent with screening candidates.
● Dispel the common misperception that the current
absence of established reimbursement means that CT
lung screening is either not recommended or of un-
proven benefit [18-22].
● Monitor and record all appointments and findings in a
similar fashion to screening mammography.
● Make multidisciplinary team of physicians available at
Lahey Hospital & Medical Center to provide manage-
ment recommendations and treatment options for all
patients with LungRADS category 4 suspicious findings.
● Note: only about 3% of a typical provider patient
panel will qualify for screening.
Our business development team arranged physician-
to-physician discussions at local in-network and out-of-
network referring PCP practices to deliver these messages.
Invited speakers gave local grand rounds designed to raise
awareness about the workup and treatment of screening-
detected early-stage lung cancer. As a result of this continu-
ingmedical education campaign, patients are nowprimarily
referred to the program through our PCP network, and we
have incurred no marketing costs for patient-directed pro-
motional activities.
To support our PCPs in the informed consent process,
we send each qualified patient a 4-page list of frequently
asked questions detailing the risks and benefits of lung
cancer screening and providing resources for smoking
cessation. Each patient is contacted by phone 1 or 2 days
Table 2. Patient demographics
Variable Group 1
Number
enrolled
386 (77%)
Average age (y) 63
Smoking history
(pack-years)
50.1
Men 53.4%
Note: NLST  National Lung Screening Trial.
Table 3. Positive results
Result Group 1 G
Positive: nodule 23.8%
Positive: infection 5.4%
S positive 5.4%Note: *  T0; NLST  National Lung Screening Trial; NRefore screening and within 3 weeks after screening by a
atient navigator to answer questions, schedule the next
creening or follow-up examination, and conduct a pa-
ient satisfaction survey. An overview of the workflow is
rovided in Figure 2.
INITIAL RESULTS
Our program began on January 9, 2012, and we reached
a total of 500 screened patients on October 8, 2012, on
whom the reported data are based.
Qualification Rate for Lung Cancer Screening
In the first few weeks of our program, 30% of patients
inquiring about screening did not meet either group of
NCCN high-risk criteria, and one-third of qualified pa-
tients met only the NCCN group 2 criteria. Over time,
the rate of patients not qualifying dropped to 18%, sug-
gesting an improvement in understanding of the high-
risk criteria by both patients and ordering physicians.
Demographics
Demographic characteristics are presented in Table 2.
Although the average age of patients in our program is
similar to that in the NLST, our overall age distribution
is more reflective of the general population than the trial
population in NLST, in which patients aged 55 to 59
years were overrepresented [6].
Positive Results
Twenty-five percent of screening examinations had pos-
itive results (30.6%, including those suspicious for infec-
tion), similar to findings reported in theNLST (Table 3).
The rate of clinically significant incidental findings in
our program was 5.6%, compared with 10.2% found
during the first year of the NLST. This may be explained
by the fact that approximately 25% of patients screened
had some prior cross-sectional imaging of the chest or
abdomen available for comparison, which presumably
roup 2 Overall NLST
4 (23%) 500 26,000
0.5 62.5 61.4
9.7 47.7 56
2.1% 51.2% 59%
up 2 Overall NLST
.1% 25% 27%*
.1% 5.6% NR
.1% 5.6% 10.2%*G
11
6
3
4ro
28
6
6 not reported.
s
v
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McKee et al/Free CT Lung Cancer Screening 591helped better characterize these findings as not clinically
significant.
Three patients in our program were diagnosed with
early-stage lung cancer, and 121 patients are currently
being followed for pulmonary nodules (Table 4).
No major complications were observed. Further anal-
ysis of these initial 500 patients is ongoing.
DISCUSSION
Any LDCT screening program must be carried out re-
sponsibly to maximize the benefit and minimize the
harms while controlling costs. Critical required elements
of such a program include a screening database, a stan-
dardized reporting system (LungRADS), and dedicated
personnel to manage appropriate patient intake as well as
communication of positive findings. If a program were
implemented nationwide in the United States, CT lung
screening has the potential to save 1,000 lives every
month [23]. However, to effectively accomplish this
across the wide spectrum of health care providers in this
country, most of whom have no prior experience in lung
screening, standardization of the operations of responsi-
ble screening programs is needed. Our own institutional
experience demonstrates that NSLT findings are gener-
alizable and that translation of the lung cancer screening
concept into clinical practice is feasible. The ACR is
uniquely positioned to develop a comprehensive practice
guideline on lung cancer screening to aid widespread,
state-of-the-art implementation of such programs.
The current lack of established reimbursement creates
a formidable barrier to lung cancer screening. Equitable
access to this screening, free of economic discrimination, is
afforded by establishment of a screening program free of
charge to qualified subjects. The ability to replicate this
approach of a free screening program will vary according to
each hospital’s unique situation, including available CT
scanner resources and time, business model, local competi-
tive environment, and patient population. High-volume,
cost-effective screening requires a decentralized informed-
consent patient referral network and systems to triage the
small number of suspicious findings for advanced evalua-
tion (LungRADS). Collaboration with local PCP networks
is critical to build a successful program, but given the de-
cades-long search for and debate over effective lung cancer
screening tools a dedicated and extensive education cam-
paign is necessary. A vigorous lobbying effort is needed to
expedite reimbursement to eliminate the health care dispar-
ities this situation creates and make CT lung screening
Table 4. Lung Cancer Diagnoses in Study Cohort
Case Tumor Stage Node Stage Meta
A T1a (2 cm) 0
B T1a (1.8 cm) 1
C T1a (1.5 cm) 0equally available to all patients at high risk. Lung cancercreening with LDCT is an example of the tremendous
alue radiologists can contribute to patient care.
TAKE-HOME POINTS
Responsible and effective CT lung screening in the absence
of established reimbursement requires several key elements:
● a mechanism for equitable patient access,
● a decentralized and informed referral base,
● a dedicated patient management system,
● standardized reporting,
● coordination betweenmultiplemedical disciplines, and
● high-volume eligible patient enrollment.
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